CSPC Pharmaceutical Group Ltd.

1093

HK1093012172

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
6.6 ^HKD	+1.23%		+14.38%	-9.09%

Apr. 26	CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023	CI
Apr. 26	CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S	CI

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

March 20, 2024 at 05:22 am EDT

CSPC Pharmaceutical Group Limited proposed ordinary final cash dividend of HKD 0.14 per share for the year ended 31 December 2023 at its shareholders' meeting to be held on 28 May 2024. Ex-dividend date: 31 May 2024. Record date: 05 June 2024.

Payment date: 26 June 2024.

Latest news about CSPC Pharmaceutical Group Ltd.

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023	Apr. 26	CI
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S	Apr. 26	CI
CSPC Pharmaceutical's EBT Buys 8.5 Million Shares	Apr. 24	MT
CSPC Pharmaceutical Group Limited and CSPC Holdings Company Limited Enter into Master Sales Agreement	Apr. 19	CI
China's drugmakers can't sell mRNA shots but haven't quit yet	Apr. 19	RE
CSPC Pharmaceutical Group Limited commences an Equity Buyback Plan for 1,190,321,973 shares, representing 10% of its issued share capital, under the authorization approved on May 31, 2023.	Apr. 16	CI
CSPC Pharma Secures Chinese Nod for Weight Managment Drug Trials	Mar. 26	MT
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration	Mar. 25	CI
CSPC Pharmaceutical’ Blood Sugar Drug Gets Registration Approval from Chinese Regulator	Mar. 22	MT
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval	Mar. 22	CI
CSPC Pharmaceutical's Cancer Drug Gets China Nod for Clinical Trials	Mar. 21	MT
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China	Mar. 20	CI
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024	Mar. 20	CI
CSPC Pharmaceutical's Profit Falls 4% on Lower Revenue, Misses Estimates	Mar. 20	MT
CSPC Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
CSPC Pharma Obtains Clinical Trial Approval in China for Anti-Tumor Drug	Mar. 19	MT
CSPC Pharmaceutical Group Limited Announces Highly Selective MAT2A Inhibitor Obtains Clinical Trial Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China	Mar. 18	CI
Nomura Adjusts CSPC Pharmaceutical Group’s Price Target to HK$9.41 From HK$8.98, Keeps at Buy	Mar. 14	MT
CSPC Pharmaceutical Obtains New Indication Nod for Mingfule Injection	Feb. 05	MT
CSPC Baike's 2023 Profit Reaches 859 Million Yuan	Jan. 25	MT
U.S. Regulator Allows CSPC Pharmaceutical to Conduct Clinical Trials for Anti-Tumor Drug	Jan. 15	MT
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration	Jan. 15	CI
Values, Inflation Outlook Lift Asian Stock Markets	Jan. 11	MT
CSPC Submits New Drug Application for Pancreatic Cancer Injectable to US FDA	Dec. 18	MT
CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA	Dec. 17	CI

Chart CSPC Pharmaceutical Group Ltd.

Duration

Period

More charts

Company Profile

CSPC Pharmaceutical Group Ltd. specializes in the development, manufacture and marketing of pharmaceutical products. Net sames by category of products break down as follows: - drugs (78.7%): innovative drugs (62.5% of sales) and common generic drugs (37.5%); - vitamin C (10.1%); - antibiotics (6.2%); - other (5%): including anhydrous and raw caffeine. Net sales are distributed geographically as follows: China (82.8%), Asia (7.2%), Europe (4.6%), the Americas (4.4%) and others (1%).

Sector

Pharmaceuticals

Calendar

2024-05-21 - Q1 2024 Earnings Release (Projected)

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for CSPC Pharmaceutical Group Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.6 HKD

Average target price

9.348 HKD

Spread / Average Target

+41.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CSPC PHARMACEUTICAL GROUP LTD.	-9.09%	9.99B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Pharmaceuticals

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

EPS Revisions